Literature DB >> 29850181

Biomarkers in malignant pleural mesothelioma: current status and future directions.

Tamkin Ahmadzada1, Glen Reid1,2, Steven Kao2,3.   

Abstract

Entities:  

Year:  2018        PMID： 29850181      PMCID： PMC5949443          DOI： 10.21037/jtd.2018.04.31

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  21 in total

1.  The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.

Authors:  Steven Chuan-Hao Kao; Rozelle Harvie; Florian Paturi; Robyn Taylor; Ross Davey; Rick Abraham; Stephen Clarke; Gavin Marx; Martin Cullen; Zoltan Kerestes; Nick Pavlakis
Journal:  Lung Cancer       Date:  2011-07-16       Impact factor: 5.705

Review 2.  Diagnosis and prognosis-review of biomarkers for mesothelioma.

Authors:  Huan H Sun; Allen Vaynblat; Harvey I Pass
Journal:  Ann Transl Med       Date:  2017-06

Review 3.  Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis.

Authors:  Zhi-De Hu; Xiao-Fei Liu; Xiao-Cui Liu; Chun-Mei Ding; Cheng-Jin Hu
Journal:  Clin Chim Acta       Date:  2014-03-07       Impact factor: 3.786

Review 4.  Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment.

Authors:  Jenette Creaney; Bruce W S Robinson
Journal:  Chest       Date:  2016-12-19       Impact factor: 9.410

5.  Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.

Authors:  Gérard Zalcman; Julien Mazieres; Jacques Margery; Laurent Greillier; Clarisse Audigier-Valette; Denis Moro-Sibilot; Olivier Molinier; Romain Corre; Isabelle Monnet; Valérie Gounant; Frédéric Rivière; Henri Janicot; Radj Gervais; Chrystèle Locher; Bernard Milleron; Quan Tran; Marie-Paule Lebitasy; Franck Morin; Christian Creveuil; Jean-Jacques Parienti; Arnaud Scherpereel
Journal:  Lancet       Date:  2015-12-21       Impact factor: 79.321

6.  Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.

Authors:  Bogdan-Dragos Grigoriu; Arnaud Scherpereel; Patrick Devos; Bachar Chahine; Marc Letourneux; Pierre Lebailly; Marc Grégoire; Henri Porte; Marie-Christine Copin; Philippe Lassalle
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

Review 7.  Progress and challenges in Mesothelioma: From bench to bedside.

Authors:  Kevin G Blyth; Daniel J Murphy
Journal:  Respir Med       Date:  2017-11-26       Impact factor: 3.415

8.  HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.

Authors:  Andrea Napolitano; Daniel J Antoine; Laura Pellegrini; Francine Baumann; Ian Pagano; Sandra Pastorino; Chandra M Goparaju; Kirill Prokrym; Claudia Canino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Clin Cancer Res       Date:  2016-01-05       Impact factor: 12.531

9.  Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.

Authors:  Michaela B Kirschner; Emily Pulford; Mir Alireza Hoda; Anita Rozsas; Kim Griggs; Yuen Yee Cheng; J James B Edelman; Steven C Kao; Rebecca Hyland; Yawen Dong; Viktoria László; Thomas Klikovits; Michael P Vallely; Michael Grusch; Balazs Hegedus; Balazs Dome; Walter Klepetko; Nico van Zandwijk; Sonja Klebe; Glen Reid
Journal:  Br J Cancer       Date:  2015-08-11       Impact factor: 7.640

Review 10.  Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.

Authors:  Bhairavi Tolani; Luis A Acevedo; Ngoc T Hoang; Biao He
Journal:  Int J Mol Sci       Date:  2018-01-13       Impact factor: 5.923
View more
  6 in total

Review 1.  An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.

Authors:  Tamkin Ahmadzada; Steven Kao; Glen Reid; Michael Boyer; Annabelle Mahar; Wendy A Cooper
Journal:  J Clin Med       Date:  2018-06-15       Impact factor: 4.241

2.  Are circulating microRNAs suitable for the early detection of malignant mesothelioma? Results from a nested case-control study.

Authors:  Daniel Gilbert Weber; Alexander Brik; Swaantje Casjens; Katarzyna Burek; Martin Lehnert; Beate Pesch; Dirk Taeger; Thomas Brüning; Georg Johnen
Journal:  BMC Res Notes       Date:  2019-02-11

Review 3.  Malignant Pleural Effusion and Its Current Management: A Review.

Authors:  Kristijan Skok; Gaja Hladnik; Anja Grm; Anton Crnjac
Journal:  Medicina (Kaunas)       Date:  2019-08-15       Impact factor: 2.948

4.  Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population.

Authors:  Tamkin Ahmadzada; Wendy A Cooper; Mikaela Holmes; Annabelle Mahar; Helen Westman; Anthony J Gill; Ina Nordman; Po Yee Yip; Abhijit Pal; Rob Zielinski; Nick Pavlakis; Adnan Nagrial; Dariush Daneshvar; Daniel Brungs; Deme Karikios; Vesna Aleksova; Juliet Burn; Rebecca Asher; Georges E Grau; Elham Hosseini-Beheshti; Glen Reid; Stephen Clarke; Steven Kao
Journal:  JTO Clin Res Rep       Date:  2020-07-16

5.  Metabolomics of a cell line-derived xenograft model reveals circulating metabolic signatures for malignant mesothelioma.

Authors:  Yun Gao; Ziyi Dai; Chenxi Yang; Ding Wang; Zhenying Guo; Weimin Mao; Zhongjian Chen
Journal:  PeerJ       Date:  2022-01-04       Impact factor: 2.984

6.  A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.

Authors:  Ming-Ming Shao; Xin Qiao; Qing-Yu Chen; Feng-Shuang Yi
Journal:  Thorac Cancer       Date:  2022-07-05       Impact factor: 3.223
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.